Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

被引：1

作者：

Cottereau, Anne Segolene ^{[1
]}

Versari, Annibale ^{[2
]}

Loft, Annika ^{[3
]}

Casasnovas, Rene-Olivier ^{[4
]}

Bellei, Monica ^{[5
]}

Ricci, Romain ^{[6
]}

Bardet, Stephane ^{[7
]}

Castagnoli, Antonio ^{[8
]}

Brice, Pauline ^{[9
]}

Raemaeker, John ^{[10
]}

Itti, Emmanuel ^{[11
]}

Forpied, Catherine ^{[11
]}

Raveloarivahy, Tiana ^{[12
]}

Girinsky, Theodore ^{[13
]}

Van der Borght, Thierry ^{[14
]}

Federico, Massimo ^{[15
]}

Hutchings, Martin ^{[16
]}

Ricardi, Umberto ^{[17
]}

Meignan, Michel ^{[18
]}

Andre, Marc ^{[19
]}

机构：

[1] Hop Henri Mondor, Nucl Med, Creteil, France

[2] Santa Maria Nuova Hosp, Reggio Emilia, Italy

[3] Copenhagen Univ Hosp, Dep Clin Physiol, Nucl Med, Rigshosp, Copenhagen, Denmark

[4] Univ Hosp, Hematol, Dijon, France

[5] Univ Modena & Reggio Emilia, Dept Diagnost & Clin Med & Publ Hlth, Modena, Italy

[6] LYSARC LYSA Hop Henri Mondor, Creteil, France

[7] CLCC Francois Baclesse, Dept Nucl Med, Caen, France

[8] Osped Santo Stefano, Nucl Med Unit, Prato, Italy

[9] Hop St Louis, APHP, Hematol, Paris, France

[10] Radboud Univ Nijmegen, Med Ctr, Hematol, Nijmegen, Netherlands

[11] Grp Hosp Mondor, APHP, Dept Nucl Med, Creteil, France

[12] European Org Res Treatment Canc, Brussels, Belgium

[13] Inst Gustave Roussy, Villejuif, France

[14] Catholic Univ Louvain, Div Nucl Med, Louvain, Belgium

[15] Univ Modena & Reggio Emilia, Dept Diagnost Clin & Publ Hlth Med, Modena, Italy

[16] Rigshosp, Dept Hematol, Copenhagen, Denmark

[17] AO Citta Salute Sci, Sez Radioterapia, Dipartimento Oncol, Turin, Italy

[18] Henri Mondor Univ Hosp, Dept Nucl Med, Creteil, France

[19] CHU UCL NAMUR, Dept Hematol, Yvoir, Belgium

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.184.184

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

184

引用

页数：5

共 36 条

[1] Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Cottereau, Anne-Segolene
Versari, Annibale
Loft, Annika
Casasnovas, Olivier
Bellei, Monica
Ricci, Romain
Bardet, Stephane
Castagnoli, Antonio
Brice, Pauline
Raemaekers, John
Deau, Benedicte
Fortpied, Catherine
Raveloarivahy, Tiana
Van Zele, Emelie
Chartier, Loic
Borght, Thierry Vander
Federico, Massimo
Hutchings, Martin
Ricardi, Umberto
Andre, Marc
Meignan, Michel
BLOOD, 2018, 131 (13) : 1456 - 1463
[2] Improved prognosis with radiotherapy in early-stage Hodgkin lymphoma: a critical analysis of the long-term data from the EORTC/LYSA/FIL H10 trial
Oertel, Michael
Eich, Hans Theodor
STRAHLENTHERAPIE UND ONKOLOGIE, 2025, 201 (01) : 85 - 87
[3] Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Andre, Marc P. E.
Girinsky, Theodore
Federico, Massimo
Reman, Oumedaly
Fortpied, Catherine
Gotti, Manuel
Casasnovas, Olivier
Brice, Pauline
van der Maazen, Richard
Re, Alessandro
Edeline, Veronique
Ferme, Christophe
van Imhoff, Gustaaf
Merli, Francesco
Bouabdallah, Reda
Sebban, Catherine
Specht, Lena
Stamatoullas, Aspasia
Delarue, Richard
Fiaccadori, Valeria
Bellei, Monica
Raveloarivahy, Tiana
Versari, Annibale
Hutchings, Martin
Meignan, Michel
Raemaekers, John
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) : 1786 - +
[4] Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma
Federico, Massimo
Fortpied, Catherine
Stepanishyna, Yana
Gotti, Manuel
van der Maazen, Richard
Cristinelli, Caterina
Re, Alessandro
Plattel, Wouter
Lazarovici, Julien
Merli, Francesco
Specht, Lena
de Colella, Jean-Marc Schiano
Hutchings, Martin
Versari, Annibale
Edeline, Veronique
Stamatoulas, Aspasia
Girinsky, Theodore
Ricardi, Umberto
Aleman, Berthe
Meulemans, Bart
Tonino, Sanne
Raemaekers, John
Andre, Marc
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 19 - +
[5] Early FDG-PET Adapted Treatment Improves the Outcome of Early FDG-PET-Positive Patients With Stages I/II Hodgkin Lymphoma (HL): Final Results of the Randomized Intergroup EORTC/LYSA/FIL H10 Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 16 - 17
[6] Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials
Fiaccadori, Valeria
Neven, Anouk
Fortpied, Catherine
Aurer, Igor
Andre, Marc
Federico, Massimo
Counsell, Nicholas
Phillips, Elizabeth H.
Clifton-Hadley, Laura
Barrington, Sally F.
Illidge, Timothy
Radford, John
Raemaekers, John M. M.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (06) : 731 - 739
[7] Verbesserte Prognose durch Radiotherapie im frühen Stadium des Hodgkin-Lymphoms – eine kritische Analyse der Langzeitdaten der EORTC/LYSA/FIL-H10-StudieImproved prognosis with radiotherapy in early-stage Hodgkin lymphoma: a critical analysis of the long-term data from the EORTC/LYSA/FIL H10 trial
Michael Oertel
Hans Theodor Eich
Strahlentherapie und Onkologie, 2025, 201 (1) : 85 - 87
[8] Omitting Radiotherapy in Early Positron Emission Tomography-Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
Raemaekers, John M. M.
Andre, Marc P. E.
Federico, Massimo
Girinsky, Theodore
Oumedaly, Reman
Brusamolino, Ercole
Brice, Pauline
Ferme, Christophe
van der Maazen, Richard
Gotti, Manuel
Bouabdallah, Reda
Sebban, Catherine J.
Lievens, Yolande
Re, Allessandro
Stamatoullas, Aspasia
Morschhauser, Frank
Lugtenburg, Pieternella J.
Abruzzese, Elisabetta
Olivier, Pierre
Casasnovas, Rene-Olivier
van Imhoff, Gustaaf
Raveloarivahy, Tiana
Bellei, Monica
van der Borght, Thierry
Bardet, Stephane
Versari, Annibale
Hutchings, Martin
Meignan, Michel
Fortpied, Catherine
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1188 - +
[9] POSITIVE INTERIM PET AFTER 2 ABVD IS MORE FREQUENT IN PATIENTS WITH UNFAVOURABLE STAGE I/II HODGKIN LYMPHOMA AND BULKY MEDIASTINUM THAN IN NON-BULKY. THE EORTC-GELA-IIL H10 TRIAL EXPERIENCE. THE EORTC-GELA-IIL H10 TRIAL EXPERIENCE
Yeddes, I
Meignan, M.
Bardet, S.
Vander Borght, T.
Ricci, R.
Itti, E.
Lumbroso, J.
Edeline, V
Olivier, P.
Borght, T., V
Reman, O.
Karcher, G.
Mundler, O.
Hutchings, M.
Versari, A.
Bellei, M.
Raemaekers, J. M. M.
Andre, M.
HAEMATOLOGICA, 2010, 95 : S49 - S49
[10] The H10 EORTC/GELA randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma
Andre, M.
Raemaekers, J.
Van der Maazen, R.
Reman, O.
Van't Veer, M.
Lutgenburg, E.
Girinski, T.
Ferme, C.
Brice, P.
Casasnovas, O.
Meignan, M.
Auduin, J.
Bosq, J.
Mounier, N.
Van Glabekke, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 7 - 7

← 1 2 3 4 →